
Fulgent Genetics FLGT
$ 16.33
0.12%
Quarterly report 2025-Q3
added 11-07-2025
Fulgent Genetics Book Value 2011-2026 | FLGT
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value Fulgent Genetics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.13 B | 1.13 B | 1.27 B | 1.17 B | 569 M | 82.8 M | 51.2 M | 54.2 M | 54.5 M | 5.15 M | 1.68 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.27 B | 1.68 M | 502 M |
Quarterly Book Value Fulgent Genetics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.12 B | 1.11 B | 1.12 B | 1.13 B | 1.13 B | 1.13 B | 1.13 B | 1.13 B | 1.26 B | 1.26 B | 1.27 B | 1.27 B | 1.28 B | - | 1.31 B | 1.17 B | 1.04 B | 921 M | 802 M | 569 M | 569 M | 569 M | 569 M | 82.8 M | 82.8 M | 82.8 M | 82.8 M | 51.2 M | 51.2 M | 51.2 M | 51.2 M | 54.2 M | 54.2 M | 54.2 M | 54.2 M | 54.5 M | 54.5 M | 54.5 M | 54.5 M | 5.15 M | 5.15 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.31 B | 5.15 M | 596 M |
Book Value of other stocks in the Diagnostics research industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
77.2 M | - | -6.23 % | $ 30.6 M | ||
|
Agilent Technologies
A
|
5.39 B | $ 116.96 | 1.23 % | $ 35.6 B | ||
|
Akumin
AKU
|
141 M | - | -17.87 % | $ 25.9 M | ||
|
Accelerate Diagnostics
AXDX
|
-22.3 M | - | -61.36 % | $ 2.46 M | ||
|
Co-Diagnostics
CODX
|
20.6 M | $ 1.72 | 2.99 % | $ 2.29 M | ||
|
Aspira Women's Health
AWH
|
-6.93 M | - | -6.19 % | $ 10.5 M | ||
|
Biocept
BIOC
|
8.86 M | - | -13.05 % | $ 7.29 M | ||
|
Castle Biosciences
CSTL
|
456 M | $ 25.0 | 2.21 % | $ 694 M | ||
|
Chembio Diagnostics
CEMI
|
17.8 M | - | 0.22 % | $ 16.8 M | ||
|
Check-Cap Ltd.
CHEK
|
-1.45 M | - | - | $ 9.42 M | ||
|
CareDx, Inc
CDNA
|
303 M | $ 21.37 | 0.66 % | $ 1.14 B | ||
|
Oxford Immunotec Global PLC
OXFD
|
16.7 M | - | - | $ 562 M | ||
|
DermTech
DMTK
|
57.2 M | - | -11.32 % | $ 2.94 M | ||
|
Enzo Biochem
ENZ
|
56.1 M | - | -8.98 % | $ 14.8 K | ||
|
Exact Sciences Corporation
EXAS
|
2.4 B | - | - | $ 19.8 B | ||
|
Illumina
ILMN
|
6.3 B | $ 128.0 | 0.09 % | $ 20.4 B | ||
|
Global Cord Blood Corporation
CO
|
4.88 B | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
132 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
16.4 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
548 M | - | 0.12 % | $ 80.1 M | ||
|
Charles River Laboratories International
CRL
|
3.21 B | $ 171.98 | 1.3 % | $ 8.52 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
1.32 B | - | - | $ 10.7 B | ||
|
Guardant Health
GH
|
-99.3 M | $ 88.84 | -0.08 % | $ 11.1 B | ||
|
Lantheus Holdings
LNTH
|
1.09 B | $ 84.31 | -0.03 % | $ 5.69 B | ||
|
HTG Molecular Diagnostics
HTGM
|
5.39 M | - | -20.0 % | $ 1.06 M | ||
|
Heska Corporation
HSKA
|
422 M | - | - | $ 1.31 B | ||
|
Interpace Biosciences
IDXG
|
22.4 M | $ 1.98 | -2.37 % | $ 8.76 M | ||
|
Medpace Holdings
MEDP
|
459 M | $ 412.77 | 0.54 % | $ 11.9 B | ||
|
Koninklijke Philips N.V.
PHG
|
11 B | $ 27.63 | 0.58 % | $ 20 B | ||
|
Motus GI Holdings
MOTS
|
2.69 M | - | -34.28 % | $ 263 K | ||
|
QIAGEN N.V.
QGEN
|
6.15 B | - | - | $ 10.6 B | ||
|
Senseonics Holdings
SENS
|
61 M | $ 7.05 | - | $ 294 M | ||
|
Neogen Corporation
NEOG
|
2.07 B | $ 9.6 | 0.58 % | $ 2.08 B | ||
|
Biomerica
BMRA
|
4.1 M | $ 2.12 | -0.93 % | $ 4.87 M | ||
|
National Research Corporation
NRC
|
14 M | $ 17.33 | 0.55 % | $ 388 M | ||
|
ICON Public Limited Company
ICLR
|
9.52 B | $ 101.21 | -0.94 % | $ 8.35 B | ||
|
Laboratory Corporation of America Holdings
LH
|
8.64 B | $ 263.81 | 0.03 % | $ 21.9 B | ||
|
Thermo Fisher Scientific
TMO
|
110 B | $ 473.8 | 0.9 % | $ 179 B | ||
|
Celcuity
CELC
|
101 M | $ 125.71 | 3.87 % | $ 5.88 B | ||
|
Trinity Biotech plc
TRIB
|
-35.2 M | $ 0.64 | -1.34 % | $ 61.9 M | ||
|
OpGen
OPGN
|
7.38 M | - | -16.95 % | $ 1.54 M | ||
|
NeoGenomics
NEO
|
837 M | $ 8.41 | 1.45 % | $ 1.08 B | ||
|
Twist Bioscience Corporation
TWST
|
473 M | $ 61.16 | 0.36 % | $ 3.66 B | ||
|
Myriad Genetics
MYGN
|
368 M | $ 4.91 | 2.72 % | $ 455 M | ||
|
Natera
NTRA
|
706 M | $ 206.02 | 1.11 % | $ 20.3 B | ||
|
Quest Diagnostics Incorporated
DGX
|
16.2 B | $ 196.49 | 0.14 % | $ 21.8 B | ||
|
Invitae Corporation
NVTA
|
102 M | - | - | $ 21.2 M | ||
|
PerkinElmer
PKI
|
7.25 B | - | -0.91 % | $ 14.7 B | ||
|
Organovo Holdings
ONVO
|
10.5 M | - | -2.3 % | $ 19.4 M |